Celldex Therapeutics, Inc. SEC filings CLDX
Celldex Therapeutics, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Oct 31, 2007. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 25, 2026 |
| DEF 14A | Proxy statement | Apr 21, 2025 | Jun 5, 2025 |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 13, 2024 |
| DEF 14A | Proxy statement | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 16, 2022 |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 17, 2021 |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | May 7, 2019 | — |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 19, 2019 |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 13, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2018 | Jun 13, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 15, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2017 | Jun 15, 2017 |
| DEF 14A | Proxy statement | Apr 21, 2016 | Jun 8, 2016 |
| DEF 14A | Proxy statement | Apr 23, 2015 | Jun 10, 2015 |
| DEF 14A | Proxy statement | Apr 9, 2014 | May 28, 2014 |
| DEF 14A | Proxy statement | Apr 23, 2013 | Jun 12, 2013 |
| DEF 14A | Proxy statement | Apr 24, 2012 | Jun 13, 2012 |
| DEF 14A | Proxy statement | Apr 26, 2011 | Jun 15, 2011 |
| DEF 14A | Proxy statement | Aug 4, 2010 | Sep 15, 2010 |
| DEF 14A | Proxy statement | Nov 6, 2009 | Dec 16, 2009 |
| DEF 14A | Proxy statement | Aug 25, 2008 | Sep 25, 2008 |
| PRE 14A | Preliminary proxy statement | Aug 13, 2008 | Sep 25, 2008 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CLDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hampton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.